*Supplementary Appendix*

***Systemic Treatment Options in Hepatocellular Carcinoma***

Lorenza Rimassa1\*, Tiziana Pressiani1, Philippe Merle2

1 Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center – IRCCS, Rozzano (Milan), Italy

2 Hepatology Unit, Groupement Hospitalier Lyon Nord, Lyon, France

**Short Title:** Systemic Treatment Options in Hepatocellular Carcinoma

**\*Corresponding Author**

Lorenza Rimassa, MD

Medical Oncology and Hematology Unit

Humanitas Cancer Center

Humanitas Clinical and Research Center - IRCCS

Via Manzoni 56, 20089 Rozzano (Milan), Italy

Tel: +390282244573

Fax: +390282244590

E-mail: [lorenza.rimassa@cancercenter.humanitas.it](mailto:lorenza.rimassa@cancercenter.humanitas.it)

Supplementary Table 1**.** Prior phase III trials of systemic treatment regimens in advanced HCC with negative results

| **Study Name/Identifier** | **Patients** | **Interventions** | **Primary Endpoint Results** | **Reference** |
| --- | --- | --- | --- | --- |
| **Phase III Studies in the First-Line Setting** | | | | |
| BRISK-FL/ [NCT00858871](https://clinicaltrials.gov/ct2/show/NCT00858871) | Advanced HCC; Child Pugh A; no prior systemic therapy  (*N*=1150) | Brivanib vs. sorafenib | Primary endpoint of OS noninferiority was not met (mOS: 9.5 vs. 9.9 months; HR=1.06; 95.8% CI: 0.93–1.22) | Johnson et al. 2013[[1](#_ENREF_1)] |
| [NCT00699374](https://clinicaltrials.gov/ct2/show/NCT00699374) | Locally advanced or metastatic HCC; Child Pugh A; no prior systemic therapy  (*N*=1074) | Sunitinib vs. sorafenib | Sunitinib significantly inferior to sorafenib (mOS: 7.9 vs. 10.2 months; HR=1.30; 95% CI: 1.13–1.50; *p*=0.0014) | Cheng et al. 2013 [[2](#_ENREF_2)] |
| [NCT01009593](https://clinicaltrials.gov/ct2/show/NCT01009593) | Advanced HCC; Child Pugh A; no prior systemic therapy  (*N*=1035) | Linifanib vs. sorafenib | No difference in OS (mOS: 9.1 vs. 9.8 months; HR=1.046; 95% CI: 0.896–1.221) | Cainap et al. 2015 [[3](#_ENREF_3)] |
| SEARCH/ [NCT0901901](https://clinicaltrials.gov/ct2/show/NCT00901901) | Advanced HCC; underlying Child Pugh class A cirrhosis; no prior systemic therapy  (*N*=720) | Sorafenib plus erlotinib vs. sorafenib plus placebo | No difference in OS (mOS: 9.5 vs. 8.5 months; HR=0.929; 95% CI: 0.78–1.11; *p*=0.408) | Zhu et al. 2015 [[4](#_ENREF_4)] |
| CALGB 80802/ [NCT01015833](https://clinicaltrials.gov/ct2/show/NCT01015833) | Advanced HCC; no prior systemic therapy; Child Pugh A  (*N*=346) | Doxorubicin plus sorafenib vs. sorafenib | No difference in OS (mOS: 9.3 vs. 10.5 months; HR=1.06; 95% CI: 0.8–1.4) | Abou-Alfa et al. 2016 [[5](#_ENREF_5)] |
| SARAH/ [NCT01482442](https://clinicaltrials.gov/ct2/show/NCT01482442) | Locally advanced or unresectable HCC or HCC after failed TACE  (*N*=467) | Selective internal radiation therapy (SIRT) with yttrium-90 resin microspheres vs. sorafenib | No difference in OS (mOS: 8.0 vs. 9.9 months; HR=1.15; 95% CI: 0.94–1.41; *p*=0.18) | Vilgrain et al. 2017 [[6](#_ENREF_6)] |
| SIRveNIB/ [NCT01135056](https://clinicaltrials.gov/ct2/show/NCT01135056) | Locally advanced HCC; no extrahepatic disease; no prior systemic therapy  (*N*=360) | SIRT with yttrium-90 resin microspheres radioembolization vs. sorafenib | No difference in OS (mOS: 8.8 vs. 10.0 months; HR=1.1; 95% CI: 0.9–1.4; *p*=0.36) | Chow et al. 2018 [[7](#_ENREF_7)] |
| **Phase III Studies in the Second-Line Setting** | | | | |
| BRISK PS/ [NCT00825955](https://clinicaltrials.gov/ct2/show/NCT00825955) | Advanced HCC; progressed on/after or were intolerant to sorafenib  (*N*=395) | Brivanib + BSC vs. placebo+ BSC | No difference in OS (mOS: 9.4 vs. 8.2 months; HR=0.89; 95.8% CI: 0.69–1.15; *p*=0.3307) | Llovet et al. 2013 [[8](#_ENREF_8)] |
| EVOLVE-1/ NCT01035229 | BCLC stage B or C HCC; progressed on/after or were intolerant to sorafenib  (*N*=546) | Everolimus + BSC vs. placebo + BSC | No difference in OS (mOS: 7.6 vs. 7.3 months; HR=1.05; 95% CI: 0.86–1.27; *p*=0.68) | Zhu et al. 2014 [[9](#_ENREF_9)] |
| REACH/NCT01140347 | BCLC stage B or C; progressed on/after or were intolerant to sorafenib  (*N*=565) | Ramucirumab + BSC vs. placebo + BSC | No difference in OS (mOS: 9.2 vs. 7.6 months; HR=0.87; 95% CI: 0.72–1.05; *p*=0.14) | Zhu et al. 2015 [[10](#_ENREF_10)] |
| S-CUBE/JapicCTI-090920  (Japan only trial) | Advanced HCC; progressed on/after or were intolerant to sorafenib  (*N*=334) | S-1 (tegafur/gimeracil/oteracil potassium) vs. placebo | No difference in OS (mOS: 11.1 vs. 11.2 months; HR=0.86; 95% CI: 0.67–1.10; *p*=0.220) | Kudo et al. 2017[[11](#_ENREF_11)] |
| METIV-HCC/ NCT01755767 | Advanced HCC with high MET expression; confirmed progression after sorafenib  (*N*=340) | Tivantinib vs. placebo | No difference in OS (mOS: 8.4 vs. 9.1 months; HR=0.97; 95% CI: 0.75–1.25; *p*=0.81) | Rimassa et al. 2018 [[12](#_ENREF_12)] |
| JET-HCC/ NCT02029157 | Advanced HCC with high MET expression; progressed on/after or were intolerant to sorafenib  (*N*=195) | Tivantinib vs. placebo | No difference in PFS (mPFS: 2.8 vs. 2.3 months; HR=0.72; 95% CI: 0.51–1.02; *p*=0.065) (Japan) | Kobayashi et al. 2017 [[13](#_ENREF_13)] |
| ADI-PEG 20/ NCT01287585 | Advanced HCC; prior systemic therapy  (*N*=635) | ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol) vs. placebo | No difference in OS (mOS: 7.8 vs. 7.4 months; HR=1.02; 95% CI: 0.847–1.233; *p*=0.88) | Abou-Alfa et al. 2018 [[14](#_ENREF_14)] |

BCLC, Barcelona Clinic Liver Cancer; BSC, best supportive care; CI, confidence interval; HCC, hepatocellular carcinoma; HR, hazard ratio; MET, mesenchymal-epithelial transition; mOS, median overall survival; mPFS, median progression-free survival; OS, overall survival; PFS, progression-free survival.

# References

1 Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Avina J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL: Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013;31:3517–3524.

2 Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E: Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013;31:4067–4075.

3 Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S: Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 2015;33:172–179.

4 Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre MA, Jensen M, Meinhardt G, Kang YK: SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015;33:559–566.

5 Abou-Alfa GK, Niedzwieski D, Knox JJ, Kaubisch A, Posey J, Tan BR, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, Siegel AB, Balletti J, Harding JJ, Schwartz LH, Goldberg RM, Bertagnolli MM, Venook AP: Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance) [abstract]. J Clin Oncol 2016;34:192.

6 Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aube C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G: Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017;18:1624–1636.

7 Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, Choo SP, Cheow PC, Chotipanich C, Lim K, Lesmana LA, Manuaba TW, Yoong BK, Raj A, Law CS, Cua IHY, Lobo RR, Teh CSC, Kim YH, Jong YW, Han HS, Bae SH, Yoon HK, Lee RC, Hung CF, Peng CY, Liang PC, Bartlett A, Kok KYY, Thng CH, Low AS, Goh ASW, Tay KH, Lo RHG, Goh BKP, Ng DCE, Lekurwale G, Liew WM, Gebski V, Mak KSW, Soo KC: SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol 2018;36:1913–1921.

8 Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW: Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013;31:3509–3516.

9 Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL, Dorval E, Peck-Radosavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT: Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014;312:57–67.

10 Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M: Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015;16:859–870.

11 Kudo M, Moriguchi M, Numata K, Hidaka H, Tanaka H, Ikeda M, Kawazoe S, Ohkawa S, Sato Y, Kaneko S, Furuse J, Takeuchi M, Fang X, Date Y, Okusaka T: S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. Lancet Gastroenterol Hepatol 2017;2:407–417.

12 Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, Lopez Lopez C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J: Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol 2018;19:682–693.

13 Kobayashi S, Ueshima K, Moriguchi M, Takayama T, Izumi N, Yoshiji H, Hino K, Oikawa T, Chiba T, Motomura K, Kato J, Yasuchika K, Ido A, Kinoshita J, Sato T, Ikeda M, Okusaka T, Kudo M, Tamura K, Furuse J: A phase 3 randomized, double-blind, placebo-controlled study of tivantinib as a second-line therapy in patients with c-Met high hepatocellular carcinoma [abstract]. Ann Oncol 2017;28:mdx369.003.

14 Abou-Alfa GK, Qin S, Ryoo BY, Lu SN, Yen CJ, Feng YH, Lim HY, Izzo F, Colombo M, Sarker D, Bolondi L, Vaccaro G, Harris WP, Chen Z, Hubner RA, Meyer T, Sun W, Harding JJ, Hollywood EM, Ma J, Wan PJ, Ly M, Bomalaski J, Johnston A, Lin CC, Chao Y, Chen LT: Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. Ann Oncol 2018;29:1402–1408.